New Evidence With BTK Inhibitor Therapy in CLL and MCL From SOHO 2023

Decera Clinical Education Oncology Podcast · Oct 4, 2023 · 20m

In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at SOHO 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of:

Matching-adjusted indirect comparison of 3 randomized phase III trials of ibrutinib for relapsed/refractory CLL

Meta-analysis of cardiovascular adverse events with second-generation BTK inhibitors in CLL

BRUIN: updated results of pirtobrutinib in covalent BTK inhibitor–pretreated MCL

ViPOR: venetoclax, ibrutinib, prednisone, obinutuzumab…